Kyowa Hakko Kirin's first therapeutic biologic product, Poteligeo (mogamulizumab), has received a reimbursement price in Japan, clearing the way for its first launch worldwide in this market later this month.
The chemokine [C-C motif] receptor 4-targeting antibody was formally approved in late March for the orphan indication of relapsed/refractory CCR4-positive...
Welcome to Scrip
Create an account to read this article
Already a subscriber?